Eli Lilly (LLY) Revenue (2009 - 2026)

Eli Lilly (LLY) has reported Revenue for 18 consecutive years, with $19.8 billion the latest figure, recorded in Q1 2026.

• Revenue for Q1 2026 came in at $19.8 billion, up 55.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.2 billion (up 47.44% YoY), and the FY2025 annual result was $65.2 billion, up 44.7% from the prior year.
• Revenue was $19.8 billion for Q1 2026 at Eli Lilly, up from $19.3 billion in the prior quarter.
• Over five years, Revenue peaked at $19.8 billion in Q1 2026 and troughed at $6.5 billion in Q2 2022.
• Average Revenue over 5 years is $11.3 billion, with a median of $9.5 billion recorded in 2023.
• Year-over-year, Revenue retreated 10.88% in 2023 and soared 55.54% in 2026.
• Over 5 years, Revenue stood at $7.3 billion in 2022, then grew by 28.1% to $9.4 billion in 2023, then soared by 44.69% to $13.5 billion in 2024, then jumped by 42.55% to $19.3 billion in 2025, then advanced by 2.63% to $19.8 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $19.8 billion in Q1 2026, $19.3 billion in Q4 2025, and $17.6 billion in Q3 2025.